Cis09 0001 01
Chemical structure diagram of the active ingredient Cisatracurium besylate, depicting its molecular components and arrangement.*
Cisatracurium Injection, Solution
Product Images NDC 63323-417
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Cisatracurium (NDC 63323-417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Cis09 0001 02
A scatter plot chart depicting data points around the intersection of two axes labeled HR (heart rate) and MAP (mean arterial pressure), showing percentage changes ranging from -60% to +60% on both axes.*
Cis09 0001 03
A scatter plot chart showing data points distributed around the zero center on both horizontal and vertical axes labeled MAP and HR, each ranging from -60% to +60%. The chart displays variability in MAP and HR percentages relative to baseline values.*
Cis09 0001 04
A chart depicting a plot with axes labeled MAP (mean arterial pressure) horizontally and HR (heart rate) vertically, each ranging from -70% to +70%. The plot shows data points clustered near the origin, indicating minimal changes in MAP and HR.*
Cis09 0001 05
A scatter plot chart showing the relationship between two variables labeled as MAP and HR, with axes ranging from -70% to +70%. The plot depicts individual data points clustered near the center, indicating a comparative distribution of percentage changes in MAP and HR.*
Cis09 0001 06
Scatter plot chart depicting the relationship between changes in mean arterial pressure (MAP) on the horizontal axis and heart rate (HR) on the vertical axis, with both axes labeled from -70% to +70%. The graph contains multiple data points plotted as stars around the origin.*
Cis09 0001 07
A scatter plot chart depicting the relationship between two variables labeled as 'MAP' on the horizontal axis and 'HR' on the vertical axis. Data points show values distributed near the center, spanning approximately -70% to +70% on both axes, likely illustrating changes in parameters related to Cisatracurium injection.*
Cis09 0001 08
A scatter plot chart displaying data points of heart rate (HR) versus mean arterial pressure (MAP) with axes ranging from -70% to +70%. The chart shows individual data points centered mostly near the origin, suggesting minimal change in these variables.*
Cis09 0001 09
A scatter plot chart showing the relationship between two variables labeled as MAP and HR, each ranging from -70% to +70%. The chart contains multiple data points distributed around the origin, illustrating variability in these two measures.*
Cis09 0001 10
Cis09 0001 11
Label for Cisatracurium Besylate Injection, USP, 10 mg (base) per 5 mL (2 mg per mL) in a 5 mL single dose vial. It is for intravenous injection, preservative-free, sterile and nonpyrogenic. The label includes warnings about its paralytic effects requiring artificial respiration and storage instructions to refrigerate at 2° to 8°C, protect from light, and use within 21 days if removed from refrigeration. Labeler is Fresenius Kabi USA, LLC.*
Cis09 0001 12
Cisatracurium Besylate Injection, USP 10 mg per 5 mL (2 mg per mL) in single-dose vials. The label indicates it is for intravenous injection, prescription use only, in a package of 10 vials of 5 mL each. Labeler is Fresenius Kabi USA, LLC. The label includes warnings about paralyzing agent and respiratory arrest risks, storage instructions, and a barcode with associated numeric codes.*
Cis09 0001 13
Label for Cisatracurium Besylate injection, USP, 2 mg per mL, intended for intravenous use only. The label includes fields to record date, time, and the person administering the drug. It also instructs to peel off and apply to syringe.*
Cis09 0001 14
Label for Cisatracurium Besylate Injection, USP 20 mg per 10 mL (2 mg/mL) solution for intravenous injection. The multi-dose vial contains 10 mL with 0.9% benzyl alcohol as a preservative. Label includes warnings about paralyzing effects and storage instructions to refrigerate between 2°C and 8°C. Labeler is Fresenius Kabi USA, LLC.*
Cis09 0001 15
Cisatracurium Besylate Injection, USP label for 20 mg per 10 mL (2 mg per mL) solution for intravenous injection. The label states 9.0% benzyl alcohol as a preservative and indicates multiple dose vials of 10 mL each. The product is labeled by Fresenius Kabi USA, LLC and includes warnings about its paralyzing agent properties. Label also contains NDC 63323-417-10 and usage instructions.*
Cis09 0001 16
Label for Cisatracurium Besylate injection, USP displaying strength of 2 mg per mL. The label indicates use for intravenous (IV) administration only and notes the presence of benzyl alcohol. There are blank fields for date, time, and user initials, alongside instructions to peel off and apply the label to a syringe.*
Cis09 0001 17
Cisatracurium Besylate Injection, USP 200 mg per 20 mL (10 mg/mL) intravenous solution in a single dose vial. The label warns that the product is a paralyzing agent causing respiratory arrest and is for ICU use only. It is preservative free and requires refrigeration at 2 to 8°C. Manufactured by Fresenius Kabi USA, LLC.*
Cis09 0001 18
Cisatracurium Besylate Injection USP label for intravenous use, 200 mg per 20 mL (10 mg/mL) strength. The label indicates 'For ICU use only' and 'Rx only.' It shows dosage form as single-dose vials with a total of 10 vials of 20 mL each. The label includes storage instructions, warnings about paralyzing agent effects, and the labeler Fresenius Kabi USA, LLC with their website.*
Cis09 0001 19
Label for Cisatracurium Besylate Injection, USP, 10 mg per mL concentration. The label indicates it is for intravenous use only and intended for ICU use. There are fields for date, time, and administrator initials. Instructions to peel off and apply the label to the syringe are also noted.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
